8-K: Curis Reports Q4 2025 Results, Advances Emavusertib Trials

Curis, Inc. announced its fourth quarter and full-year 2025 financial results, alongside significant clinical progress for its lead drug candidate, emavusertib, and a recent $80.8 million private placement.

Summary

• Curis reported net income of $19.4 million, or $1.23 per share, for the fourth quarter of 2025, a significant improvement from a net loss of $9.6 million, or $1.25 per share, in Q4 2024.
• The full-year 2025 net loss was $7.6 million, or $0.58 per share, substantially reduced from a net loss of $43.4 million, or $6.88 per share, in 2024.
• Revenues, net, were $1.1 million for Q4 2025 and $9.4 million for the full year 2025, down from $3.3 million and $10.9 million in the respective 2024 periods, primarily due to the sale of Erivedge royalty interest.
• The company sold its interest in Curis Royalty LLC, including Erivedge intellectual property, for $2.5 million upfront and a release of $27.2 million in liability related to the sale of future royalties, resulting in a non-cash gain.
• In the TakeAim Lymphoma study for Primary CNS Lymphoma (PCNSL), emavusertib in combination with ibrutinib achieved a 100% objective response rate (ORR) in 5 BTKi-naive patients and a 37% ORR in 19 BTKi-experienced patients.
• Initial clinical data in Secondary CNS Lymphoma (SCNSL) showed 1 complete response (CR) and 1 stable disease (SD) with a 38% reduction in disease burden in 2 BTKi-progressed patients treated with emavusertib and ibrutinib.
• A Phase 2 clinical study of emavusertib in combination with zanubrutinib was initiated for Chronic Lymphocytic Leukemia (CLL), aiming for deeper responses and potential time-limited treatment.
• In the AML triplet study, 5 of 8 patients (62.5%) achieved MRD conversion (MRD+ to undetectable) when emavusertib was added to azacitidine and venetoclax.
• Curis closed a private placement in January 2026, generating initial gross proceeds of approximately $20.2 million, with potential for up to an additional $60.6 million from warrant exercises.
• Cash and cash equivalents totaled $5.1 million as of December 31, 2025.
• The company believes its cash, combined with initial PIPE proceeds and expected Series B warrant exercise, will fund planned operations into the second half of 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, driven by strong clinical data in key programs, a significant improvement in quarterly financial performance (albeit aided by an asset sale), and a successful capital raise that extends the cash runway. However, the underlying revenue decline and continued need for substantial future funding temper the overall sentiment.

Positives

• Achieved net income of $19.4 million in Q4 2025, a significant turnaround from a net loss in the prior year period.
• Reduced full-year net loss from $43.4 million in 2024 to $7.6 million in 2025.
• Strong clinical efficacy demonstrated in the TakeAim Lymphoma study for PCNSL, with a 100% objective response rate in BTKi-naive patients.
• Promising initial efficacy signals observed in SCNSL patients, including a complete response.
• Initiated a Phase 2 clinical study in CLL, targeting a paradigm shift in treatment outcomes with deeper responses.
• Positive MRD conversion rates (62.5%) in AML patients receiving emavusertib combination therapy.
• Successfully completed a private placement, securing up to $80.8 million in potential gross proceeds, significantly extending the cash runway.
• Emavusertib has been granted orphan drug designation by both FDA and EMA in PCNSL.
• Reduced research and development expenses by $10.3 million and general and administrative expenses by $2.8 million year-over-year.

Negatives

• Net revenues declined for both the fourth quarter and full year 2025, primarily due to the sale of the Erivedge royalty interest.
• Nine patients in the PCNSL study were unable to complete one cycle of treatment due to adverse events unrelated to treatment, disease progression, or transition to hospice care.
• Cash and cash equivalents were low at $5.1 million as of December 31, 2025, prior to the January 2026 PIPE financing.

Risks

• Curis may experience adverse results, delays, and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in projected time frames, if at all.
• Drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies, and/or may never achieve the requisite regulatory approvals needed for commercialization.
• Favorable results seen in preclinical studies and early clinical trials of drug candidates may not be replicated in later trials.
• The company is dependent on the success of emavusertib, and any delays in its development could have a material adverse effect on the business.
• There is no guarantee that collaboration agreements with Aurigene or NCI will continue for their full terms, or that parties will maintain necessary financial and other resources.
• Curis will require substantial additional capital to fund its business and does not have sufficient cash on hand to support current operations within the next 12 months from the press release date without additional funding.
• If unable to obtain sufficient funding, the company will be forced to delay, reduce in scope, or eliminate the development of emavusertib, including related clinical trials and operating expenses.
• Curis faces substantial competition in the biotechnology industry.
• The company and its collaborators face the risk of potential adverse decisions made by regulatory authorities (FDA, EMA), investigational review boards, and publication review bodies.
• Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time-consuming patent litigation.
• Unstable market and economic conditions, natural disasters, public health crises, political crises, and other events outside of Curis's control could significantly disrupt its operations or the operations of third parties.
• The company faces risks related to its ability to regain and maintain its listing on the Nasdaq Capital Market.

Future Outlook

Curis anticipates its current cash and cash equivalents, combined with the initial gross proceeds from the January 2026 PIPE Financing and expected gross proceeds from the exercise of Series B Warrants (upon dosing the fifth CLL patient later this year), will enable planned operations into the second half of 2027. The company intends to continue enrolling PCNSL patients in the TakeAim Lymphoma study to support accelerated approval filings in the US and Europe. Further development of emavusertib in AML is planned with additional funding.

Management Comments

• Curis management will host a conference call today, March 19, 2026, at 4:30 p.m. ET, to discuss the business update and these financial results.
• The goal of combining emavusertib with a BTKi is to enable a dual blockade of NF-kB, a key driver of disease in CLL and NHL, by inhibiting both the TLR and BCR pathways.
• Previous clinical studies have shown that adding emavusertib, which blocks the TLR pathway, to a BTKi regimen can enable patients with NHL to achieve deeper responses, including complete remission or undetectable minimal residual disease (MRD) and the potential for time-limited treatment, outcomes which represent the potential for a paradigm shift in the management of CLL.

Industry Context

StockSavvy.ai notes that the oncology space, particularly for lymphomas and leukemias, is highly competitive with a strong focus on combination therapies to improve response rates and achieve deeper, more durable remissions. Emavusertib's mechanism of action (IRAK4 and FLT3 inhibition) and its combination with BTK inhibitors represent a strategy to address resistance mechanisms and enhance efficacy, aligning with broader industry efforts to develop targeted therapies for difficult-to-treat hematologic malignancies. The pursuit of accelerated approval pathways for PCNSL also reflects the urgent unmet medical need in this indication.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against. Therefore, a detailed comparison to industry standards cannot be made based solely on the provided text.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical data, extended cash runway, and improved financial position. However, dilution from the PIPE financing and potential warrant exercises is a factor.
• Patients: Potential for new and improved treatment options for PCNSL, SCNSL, CLL, and AML patients if emavusertib proves safe and effective in ongoing and future clinical trials.
• Employees: Continued employment and progress on drug development programs, contributing to job stability and potential growth opportunities.
• Creditors: Improved financial stability and cash position resulting from the capital raise reduce immediate credit risk.

Next Steps

• Continue enrolling PCNSL patients in the TakeAim Lymphoma study to support accelerated approval filings in the US and Europe.
• Public announcement of dosing the fifth patient in the Phase 2 clinical trial in CLL, expected later this year.
• Curis management will host a conference call today, March 19, 2026, at 4:30 p.m. ET, to discuss the business update and financial results.
• Plans to continue development of emavusertib in AML with additional funding.

Key Dates

Recommendation

The company presents promising clinical data for emavusertib across multiple oncology indications and has significantly bolstered its financial position through a recent private placement and asset sale, extending its cash runway. This progress is positive for a clinical-stage biotechnology company. However, Curis remains pre-commercial, with substantial future funding requirements and inherent risks associated with drug development, including potential for unexpected toxicities or failure to achieve regulatory approvals. The decline in royalty revenues also highlights the company's reliance on its pipeline. A 'hold' recommendation is appropriate for existing investors, acknowledging the positive developments while recognizing the speculative nature and significant risks that persist until further clinical milestones are achieved and a clearer path to commercialization emerges.

Keywords

Biotechnology, Oncology, Emavusertib, IRAK4 inhibitor, FLT3 inhibitor, Lymphoma, CLL, AML, PCNSL, SCNSL, BTK inhibitor, Ibrutinib, Zanubrutinib, Clinical Trials, Phase 2, Orphan Drug, Financial Results, Private Placement, NASDAQ